These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26282229)

  • 1. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.
    Karlsson L; Lundkvist J; Psachoulia E; Intorcia M; Ström O
    Osteoporos Int; 2015 Oct; 26(10):2401-11. PubMed ID: 26282229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
    Hadji P; Kyvernitakis I; Kann PH; Niedhart C; Hofbauer LC; Schwarz H; Kurth AA; Thomasius F; Schulte M; Intorcia M; Psachoulia E; Schmid T
    Osteoporos Int; 2016 Oct; 27(10):2967-78. PubMed ID: 27172934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.
    Borek DM; Smith RC; Gruber CN; Gruber BL
    Osteoporos Int; 2019 Jul; 30(7):1455-1464. PubMed ID: 31011760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
    Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
    Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
    Durden E; Pinto L; Lopez-Gonzalez L; Juneau P; Barron R
    Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence with denosumab and zoledronic acid among older women: a population-based cohort study.
    Tremblay É; Perreault S; Dorais M
    Arch Osteoporos; 2016 Dec; 11(1):30. PubMed ID: 27679503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients.
    Morizio P; Burkhart JI; Ozawa S
    Ann Pharmacother; 2018 Oct; 52(10):1031-1041. PubMed ID: 29616561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis.
    Yang J; Guo X; Cui Z; Guo H; Dong JN
    Front Endocrinol (Lausanne); 2024; 15():1431676. PubMed ID: 39286276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.
    Fatoye F; Smith P; Gebrye T; Yeowell G
    BMJ Open; 2019 Apr; 9(4):e027049. PubMed ID: 30987990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic.
    Fuksa L; Vytrisalova M
    Curr Med Res Opin; 2015; 31(9):1645-53. PubMed ID: 26121231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
    Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
    Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis.
    Torre C; Guerreiro J; Mendes Z; Miranda A; Bragança F; Cristino J; Canhão H; Branco JC
    Acta Reumatol Port; 2019; 44(2):114-125. PubMed ID: 31280276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
    Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
    Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
    Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.